AR089737A1 - Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio - Google Patents
Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminioInfo
- Publication number
- AR089737A1 AR089737A1 ARP130100131A ARP130100131A AR089737A1 AR 089737 A1 AR089737 A1 AR 089737A1 AR P130100131 A ARP130100131 A AR P130100131A AR P130100131 A ARP130100131 A AR P130100131A AR 089737 A1 AR089737 A1 AR 089737A1
- Authority
- AR
- Argentina
- Prior art keywords
- aiooh
- antigen
- antigens
- hepatitis
- adsorberse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un procedimiento para preparar una composición vacunal que comprende al menos oxi-hidróxido de aluminio (AIOOH), y al menos el antígeno de superficie de la hepatitis B y el antígeno de Haemophilus influenzae tipo b. De acuerdo con la presente, el antígeno de superficie de la hepatitis B se mantiene adsorbido sobre el AIOOH mientras que el antígeno de Hib se mantiene no adsorbido. A tal efecto: se procede a adsorber el antígeno de superficie de la hepatitis B sobre AIOOH a fin de obtener un complejo AIOOH/HBsAg, luego se mezcla dicho complejo AIOOH/HBsAg con el antígeno de Hib en presencia de aminoácidos catiónicos a una concentración de al menos 100 mg/l, y de iones Fosfato a una concentración de 35 a 45 mMol/I. Reivindicación 7: Procedimiento de acuerdo con la reivindicación 1, que se caracteriza porque consiste además en: preparar una composición que comprende al menos un antígeno seleccionado entre los antígenos de la difteria, del tétanos, de la polio, de la tos convulsa, así como también del oxi-hidroxi de aluminio, y mezclar dicho complejo AIOOH/HBsAg con dicha composición, antes de proceder a la mezcla con el antígeno de Hib.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1250464A FR2985663B1 (fr) | 2012-01-17 | 2012-01-17 | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089737A1 true AR089737A1 (es) | 2014-09-10 |
Family
ID=47714410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100131A AR089737A1 (es) | 2012-01-17 | 2013-01-16 | Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9358294B2 (es) |
| EP (1) | EP2804628B1 (es) |
| JP (2) | JP6199310B2 (es) |
| KR (1) | KR102019848B1 (es) |
| CN (1) | CN104039348B (es) |
| AP (1) | AP2014007848A0 (es) |
| AR (1) | AR089737A1 (es) |
| AU (1) | AU2013210927B2 (es) |
| BR (1) | BR112014017416B1 (es) |
| CA (1) | CA2861304C (es) |
| CR (1) | CR20140356A (es) |
| CY (1) | CY1119206T1 (es) |
| DK (1) | DK2804628T3 (es) |
| EA (1) | EA026058B1 (es) |
| ES (1) | ES2625011T3 (es) |
| FR (1) | FR2985663B1 (es) |
| GE (1) | GEP201706642B (es) |
| GT (1) | GT201400120A (es) |
| HK (1) | HK1204293A1 (es) |
| HR (1) | HRP20170692T1 (es) |
| HU (1) | HUE032539T2 (es) |
| IL (1) | IL233643A (es) |
| LT (1) | LT2804628T (es) |
| MX (1) | MX349411B (es) |
| NZ (1) | NZ627345A (es) |
| PE (1) | PE20141515A1 (es) |
| PH (1) | PH12014501546B1 (es) |
| PL (1) | PL2804628T3 (es) |
| PT (1) | PT2804628T (es) |
| RS (1) | RS55962B1 (es) |
| SI (1) | SI2804628T1 (es) |
| UA (1) | UA113000C2 (es) |
| WO (1) | WO2013107988A1 (es) |
| ZA (1) | ZA201405431B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
| WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
| EP4327820A1 (en) | 2021-04-20 | 2024-02-28 | KM Biologics Co., Ltd. | Liquid sextuple vaccine composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0835663T3 (da) * | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
| US6790445B1 (en) * | 1997-02-06 | 2004-09-14 | Merck & Co., Inc. | Preservatives for vaccines |
| ATE470434T1 (de) * | 1997-02-06 | 2010-06-15 | Merck Sharp & Dohme | Thimerosal-freie konservierungsmittel für impfstoffe |
| DK1028750T3 (da) * | 1997-09-15 | 2006-05-22 | Sanofi Pasteur Msd | Fremgangsmåde til fremstilling af multivalente vacciner |
| EP1409013B1 (en) * | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| CA2456713A1 (en) | 2001-08-07 | 2003-02-20 | Antonio Sereno | Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| FR2828406B1 (fr) * | 2001-08-08 | 2005-06-24 | Aventis Pasteur | Composition vaccinale bivalente havi |
| GB0610140D0 (en) * | 2006-05-22 | 2006-06-28 | Insense Ltd | Protein stability |
| PE20100366A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
-
2012
- 2012-01-17 FR FR1250464A patent/FR2985663B1/fr active Active
-
2013
- 2013-01-16 AR ARP130100131A patent/AR089737A1/es not_active Application Discontinuation
- 2013-01-17 DK DK13704171.1T patent/DK2804628T3/en active
- 2013-01-17 CA CA2861304A patent/CA2861304C/fr active Active
- 2013-01-17 JP JP2014552680A patent/JP6199310B2/ja active Active
- 2013-01-17 UA UAA201409180A patent/UA113000C2/uk unknown
- 2013-01-17 US US14/372,695 patent/US9358294B2/en active Active
- 2013-01-17 LT LTEP13704171.1T patent/LT2804628T/lt unknown
- 2013-01-17 EA EA201491387A patent/EA026058B1/ru not_active IP Right Cessation
- 2013-01-17 ES ES13704171.1T patent/ES2625011T3/es active Active
- 2013-01-17 CN CN201380005797.8A patent/CN104039348B/zh active Active
- 2013-01-17 WO PCT/FR2013/050106 patent/WO2013107988A1/fr active Application Filing
- 2013-01-17 MX MX2014007850A patent/MX349411B/es active IP Right Grant
- 2013-01-17 HU HUE13704171A patent/HUE032539T2/hu unknown
- 2013-01-17 GE GEAP201313552A patent/GEP201706642B/en unknown
- 2013-01-17 NZ NZ627345A patent/NZ627345A/en unknown
- 2013-01-17 KR KR1020147022200A patent/KR102019848B1/ko active IP Right Grant
- 2013-01-17 EP EP13704171.1A patent/EP2804628B1/fr active Active
- 2013-01-17 PE PE2014001091A patent/PE20141515A1/es active IP Right Grant
- 2013-01-17 SI SI201330643A patent/SI2804628T1/sl unknown
- 2013-01-17 RS RS20170449A patent/RS55962B1/sr unknown
- 2013-01-17 AP AP2014007848A patent/AP2014007848A0/xx unknown
- 2013-01-17 AU AU2013210927A patent/AU2013210927B2/en active Active
- 2013-01-17 PL PL13704171T patent/PL2804628T3/pl unknown
- 2013-01-17 PT PT137041711T patent/PT2804628T/pt unknown
- 2013-01-17 BR BR112014017416-4A patent/BR112014017416B1/pt active IP Right Grant
-
2014
- 2014-06-19 GT GT201400120A patent/GT201400120A/es unknown
- 2014-07-03 PH PH12014501546A patent/PH12014501546B1/en unknown
- 2014-07-14 IL IL233643A patent/IL233643A/en active IP Right Grant
- 2014-07-23 CR CR20140356A patent/CR20140356A/es unknown
- 2014-07-23 ZA ZA2014/05431A patent/ZA201405431B/en unknown
-
2015
- 2015-05-26 HK HK15104967.4A patent/HK1204293A1/xx unknown
-
2017
- 2017-05-10 HR HRP20170692TT patent/HRP20170692T1/hr unknown
- 2017-05-31 CY CY20171100571T patent/CY1119206T1/el unknown
- 2017-08-23 JP JP2017160109A patent/JP6356886B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6430434A2 (es) | Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas | |
| MX2023000211A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
| MY150706A (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
| CO6430435A2 (es) | Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas | |
| MX2015008027A (es) | Proceso de glicoconjugacion. | |
| MX343914B (es) | Adsorcion de inmunopotenciadores en sales metalicas insolubles. | |
| MX2010008799A (es) | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. | |
| MX359517B (es) | Composiciones, formulaciones y metodos de compuestos lipidicos modificadores de respuestas inmunitaria. | |
| AR089737A1 (es) | Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio | |
| NI201200140A (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| EP4218808A3 (en) | Adjuvant and vaccine compositions | |
| EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
| RU2014140336A (ru) | Иммунологически полезные соли аргинина | |
| MX366051B (es) | Composiciones del virus del síndrome reproductor y respiratorio de porcino y sus usos. | |
| PH12015500061A1 (en) | Method for preparing substituted triazolopyridines | |
| WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing | |
| NI201200141A (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
| WO2010111586A3 (en) | Mucosal immunization | |
| JP2016502995A5 (es) | ||
| TR201910409T4 (tr) | Sitrülin barındıran adjuvan bileşimi. | |
| TH149877A (th) | วิธีสำหรับการผสมสูตรวัคซีนที่มีแอนติเจนอย่างน้อยสองชนิดที่สามารถดูดซับบนอลูมิเนียม ออกซิไฮดรอกไซด์ | |
| MX345947B (es) | Procedimiento para preparar una composición de vacuna. | |
| AR097217A1 (es) | Composiciones inmunógenas de combinación | |
| RU2013151531A (ru) | Способ получения трифторида бора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |